Related Experiment Video
Updated: May 4, 2026
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
1.1K
German psoriasis registry PsoBest: objectives, methodology and baseline data.
Matthias Augustin1, Christina Spehr, Marc A Radtke
1IVDP - Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Summary
The PsoBest registry tracks long-term psoriasis outcomes. Patients in this study had higher disease severity and more psoriatic arthritis than in a previous national study.
Area of Science:
- Dermatology
- Clinical Research
- Public Health
Background:
- The German Psoriasis Registry (PsoBest) collects data on long-term psoriasis management.
- It focuses on efficacy, safety, patient-reported benefits, and treatment strategies.
Purpose of the Study:
- To establish baseline characteristics of patients initiating new systemic or biologic therapy for moderate to severe psoriasis.
- To compare these baseline characteristics with a national health care study (PsoHealth 2007).
Main Methods:
- PsoBest enrolled patients starting their first conventional systemic agent or biologic for moderate to severe psoriasis.
- Data were collected via standardized physician and patient forms over a five-year observation period.
- Baseline data from patients recruited by December 31, 2012, were analyzed.
Main Results:
- 2,556 patients were recruited from 199 centers, with 808 receiving biologics and 1,651 conventional systemic therapy.
- PsoBest patients exhibited higher disease severity (PASI, DLQI, EQ-5D VAS) compared to PsoHealth 2007.
- PsoBest patients had shorter disease duration, were younger, and had higher rates of psoriatic arthritis and nail psoriasis.
Conclusions:
- Patients enrolled in the PsoBest registry represent a population with a high disease burden.
- This highlights the need for effective long-term management strategies for severe psoriasis.
